2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103238
    RSVA405 140405-36-3 99.72%
    RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity.
    RSVA405
  • HY-106697
    Ponalrestat 72702-95-5 99.51%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
    Ponalrestat
  • HY-109555
    Insulin glulisine 207748-29-6
    Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes.
    Insulin glulisine
  • HY-112472
    S3969 1027997-01-8 98.38%
    S3969 is a potent and reversible activator of the human epithelial sodium channel (hENaC). The apparent EC50 for S3969 activation of hENaC is 1.2 μm.
    S3969
  • HY-114011
    AMG7703 1103523-24-5 99.24%
    AMG7703 is a selective and allosteric agonists of FFA2 (GPR43), the receptor for short-chain fatty acids (SCFAs), acetate, and propionate. AMG7703 can be used to research for in inflammatory and metabolic.
    AMG7703
  • HY-117029
    NAAD sodium 104809-30-5 ≥98.0%
    NAAD sodium (Deamido nad sodium), a functional NAD+ precursor, is the substrate of glutamine-dependent NAD+ synthetase. NAAD sodium is used to study the structure of nicotinate mononucleotide adenylyltransferases.
    NAAD sodium
  • HY-120669
    PF-06761281 1854061-19-0 99.32%
    PF-06761281 (Compound 4a) is a potent, orally active, partial selective sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor with IC50 values of 0.51, 13.2 and 14.1 µM against HEKNaCT, HEKNaDC1 and HEKNaDC3, respectively.
    PF-06761281
  • HY-12398A
    TEI-9648 173388-21-1 99.30%
    TEI-9648, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9648 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9648 also inhibits HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9648 has the potential for bone metabolism research.
    TEI-9648
  • HY-126217
    hGPR91 antagonist 1 1314796-00-3 99.94%
    hGPR91 antagonist 1 (Compound 4c) is a potent and selective GPR91 antagonist with an IC50 of 7 nM for human GPR91.
    hGPR91 antagonist 1
  • HY-126995
    Glycohyodeoxycholic acid 13042-33-6 ≥98.0%
    Glycohyodeoxycholic acid is a major metabolite of Hyodeoxycholic acid in humans. Glycohyodeoxycholic acid has preventative effects on gallstone formation.
    Glycohyodeoxycholic acid
  • HY-128747
    α-D-Glucose-1-phosphate disodium 56401-20-8 ≥99.0%
    α-D-Glucose-1-phosphate disodium is used as a starting material for synthesis of glucuronic acid. α-D-Glucose-1-phosphate disodium can be used as a cytostatic compound essential for cardiopathic therapy, as an antibiotic, as an immunosuppressive agent, and as a circulatory system therapy element.
    α-D-Glucose-1-phosphate disodium
  • HY-129630
    Tetrahydrocortisol 53-02-1 ≥99.0%
    Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity.
    Tetrahydrocortisol
  • HY-130466
    Stearoyl-L-carnitine chloride 32350-57-5 ≥99.0%
    Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM.
    Stearoyl-L-carnitine chloride
  • HY-135391
    Ezetimibe phenoxy glucuronide 190448-57-8 99.77%
    Ezetimibe phenoxy glucuronide (Ezetimibe glucuronide) is the active metabolite of Ezetimibe. Antihyperlipoproteinemic activity. Ezetimibe is a potent cholesterol absorption inhibitor.
    Ezetimibe phenoxy glucuronide
  • HY-19528S
    SAH-d4 ≥99.0%
    SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
    SAH-d4
  • HY-B0172S
    Lithocholic acid-d4 83701-16-0 99.72%
    Lithocholic acid-d4 is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid[1].
    Lithocholic acid-d4
  • HY-114118F
    Semaglutide, FITC labeled
    Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting GLP-1 alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
    Semaglutide, FITC labeled
  • HY-114295A
    Geranyl diphosphate triammonium 116057-55-7 ≥98.0%
    Geranyl diphosphate triammonium is a key intermediate in the isoprenoid biosynthesis pathway (IBP). Geranyl diphosphate triammonium plays key roles in cellular metabolism and is responsible for the production of both sterol and non-sterol isoprenoids.
    Geranyl diphosphate triammonium
  • HY-145934A
    UDP-GlcNAz disodium 1611490-64-2 99.74%
    UDP-GlcNAz disodium (UDP-N-azidoacetylgalactosamine disodium) is the analogue of UDP-GlcNAc (HY-112174). UDP-GlcNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc (disodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    UDP-GlcNAz disodium
  • HY-W004049
    3-Hydroxybenzoic acid 99-06-9 99.89%
    3-Hydroxybenzoic acid is an orally active endogenous metabolite. 3-Hydroxybenzoic acid is an agonist for GPR81 and GPR109A. 3-Hydroxybenzoic acid acts as stress response desensitizers. 3-Hydroxybenzoic acid can be used for anti-inflammatory and analgesic study.
    3-Hydroxybenzoic acid
Cat. No. Product Name / Synonyms Application Reactivity